Page tree

StatusReady for review
Version

0.1

Version in PROD

Descriptions:

Termdescription typeLanguage/acceptabilityLanguage/acceptabilityCase significance

[Occurrence] [Clinical course] [Substance and/or product] dependence (disorder) (disorder)

FSNus:Pgb:Pci

[Occurrence] [Clinical course] [Substance and/or product] dependence

SYNus:Pgb:Pci
[Occurrence] [Clinical course] dependence caused by [Substance and/or product]SYNus:Agb:Aci


Concept model:

Definition status:  


900000000000073002 |Defined (core metadata concept)|

Applies to:

191816009 |Drug dependence (disorder)|

Template language


Link to the misaligned concept report:

https://docs.google.com/spreadsheets/d/1EC3aObnnsvZ7aixBndk5yfvInz7iXGnv5wf4zD-IMlg/edit#gid=3

Rules for description generation: 

  1. Apply General rules for generating descriptions for templates;
  2. Apply Enhancements for the Template Language;

JIRA ticket:

EDITORIAL GUIDELINES for Causative agent (attribute):

Hierarchy

Concept type

Allowed

Exception

Examples and Notes

SubstanceBaseyesnone

Concepts representing a substance base should be modeled using a Causative agent that is a descendant of 105590001 |Substance (substance)|.

Examples:

  • 231474005 |Diazepam dependence (disorder)|

Classification results are expected to be consistent with the modeling of the concept selected as the Causative agent in the Substance hierarchy.

SubstanceModificationnonone

No use case has been identified for use of this concept type for modeling in this subhierarchy.

SubstanceStructure grouperyesnone

Concepts representing a structure grouper should be modeled using a Causative agent that is a descendant of 105590001 |Substance (substance)|.

  • 231472009 |Barbiturate dependence (disorder)|

Classification results are expected to be consistent with the modeling of the concept selected as the Causative agent in the Substance hierarchy.

SubstanceDisposition grouperyesnone

Concepts representing a disposition grouper should be modeled using a Causative agent that is a descendant of 105590001 |Substance (substance)|.

  • 75544000 |Opioid dependence (disorder)|

Classification results are expected to reflect that the adverse reaction concepts are descendants of the appropriate disposition grouper based on the modeling of the 726542003 |Has disposition (attribute)| attribute in the substance hierarchy.

SubstanceRole groupernonone

 Concepts representing a role grouper should be modeled using a Causative agent that is a descendant of 105590001 |Substance (substance)|.

  • 2403008 |Psychoactive substance dependence (disorder)|

Classification results are expected to reflect that the adverse reaction concepts are descendants of the appropriate disposition grouper based on the modeling of the 726542003 |Has disposition (attribute)| attribute in the substance hierarchy.

ProductMedicinal product-containingyesnone

Examples to be added - pending implementation of roles and products as causative agents

ProductRole grouperyesnone

Examples to be added - pending implementation of roles and products as causative agents

ProductStructure groupernonone

No use case has been identified for use of this concept type for modeling in this subhierarchy. Medicinal product-containing concepts can be used for modeling in this subhierarchy.


ProductDisposition groupernononeNo use case has been identified for use of this concept type for modeling in this subhierarchy. Medicinal product-containing concepts can be used for modeling in this subhierarchy.
ProductMedicinal product-onlynononeNo use case has been identified for use of this concept type for modeling in this subhierarchy. Medicinal product-containing concepts can be used for modeling in this subhierarchy.
ProductMedicinal product form-containingnononeNo use case has been identified for use of this concept type for modeling in this subhierarchy. Medicinal product-containing concepts can be used for modeling in this subhierarchy.
ProductMedicinal product form-onlynononeNo use case has been identified for use of this concept type for modeling in this subhierarchy. Medicinal product-containing concepts can be used for modeling in this subhierarchy.
ProductClinical drugnononeNo use case has been identified for use of this concept type for modeling in this subhierarchy. Medicinal product-containing concepts can be used for modeling in this subhierarchy.

7 Comments

  1. Hi Yongsheng Gao

    As discussed in the last QI call, here is the draft template for Drug dependence concepts. Kindly review the template and let me know if I can go ahead with normalization.

    Similar to "Harmful pattern of use of  [substance and/or product] (disorder) - v1.0", I anticipate changes to the terming and modelling once the Mental and Behavioural Health Clinical Reference Group has finalized their decision regarding substance use/abuse/ misuse/ dependance etc:

    However, as noted during the QI call, this template can be used as a starting point and to making all current children consistently modelled.

    Thanks,

    Farzaneh

  2. Substance-Modification not allowed?

    How are the various amphetamine type substances to be modelled? (e.g. methamphetamine, pseudoephedrine, MDMA etc)

    The currently modelling is patchy, but some candidate substances are currently modelled with this property (is modification of) - 288459003|Methylenedioxymethamphetamine|
    Which is used to define = 724704009|MDMA (methylenedioxymethamphetamine) dependence with current use|

    1. Hi Matt Cordell 

      Thanks for the feedback and raising a valid point. I will take your comment for internal discussion and will get back to you with an update.

      Thanks,

      Farzaneh

  3. Hi Farzaneh Ashrafi , the template looks fine. Please go ahead with the normalisation for the QI project. 

      1. Yongsheng Gao The editorial rules are more specific than the template.

        1. Thanks Matt Cordell , your feedback is noted for discussion. The normalisation in the QI project only converts the existing concept model to the authoring form (proximal primitive parent). The editorial guide and modelling will be updated after the recommendation is finalised by the clinical reference group. Then, we can move to the next step for the implementation of this template.